Allspring Global Investments Holdings LLC raised its stake in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) by 197.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,406 shares of the biopharmaceutical company's stock after acquiring an additional 933 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in Prometheus Biosciences were worth $82,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in RXDX. Amundi bought a new position in Prometheus Biosciences during the 2nd quarter valued at $100,000. Amalgamated Bank acquired a new stake in shares of Prometheus Biosciences during the first quarter worth $143,000. Quantbot Technologies LP raised its holdings in shares of Prometheus Biosciences by 1,128.1% during the second quarter. Quantbot Technologies LP now owns 5,158 shares of the biopharmaceutical company's stock worth $145,000 after purchasing an additional 4,738 shares during the period. Legal & General Group Plc raised its holdings in shares of Prometheus Biosciences by 7.4% during the second quarter. Legal & General Group Plc now owns 5,613 shares of the biopharmaceutical company's stock worth $158,000 after purchasing an additional 389 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Prometheus Biosciences during the first quarter worth $201,000. 78.31% of the stock is currently owned by institutional investors.

Prometheus Biosciences Stock Performance

NASDAQ:RXDX opened at $116.12 on Monday. Prometheus Biosciences, Inc. has a twelve month low of $21.50 and a twelve month high of $122.75. The company has a current ratio of 11.19, a quick ratio of 11.19 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average of $94.83 and a 200-day moving average of $65.30. The firm has a market cap of $4.87 billion, a price-to-earnings ratio of -34.66 and a beta of -0.46.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on RXDX shares. Stifel Nicolaus increased their price objective on shares of Prometheus Biosciences from $50.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday, November 1st. Oppenheimer increased their price objective on shares of Prometheus Biosciences from $61.00 to $125.00 and gave the stock an "outperform" rating in a report on Thursday, December 8th. Credit Suisse Group increased their price objective on shares of Prometheus Biosciences from $59.00 to $142.00 and gave the stock an "outperform" rating in a report on Thursday, December 8th. Wells Fargo & Company increased their price objective on shares of Prometheus Biosciences from $71.00 to $164.00 in a report on Thursday, December 8th. Finally, Royal Bank of Canada raised their target price on shares of Prometheus Biosciences from $66.00 to $111.00 in a research note on Wednesday, December 7th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $107.80.

Insider Transactions at Prometheus Biosciences

In other news, CFO Keith W. Marshall sold 5,000 shares of Prometheus Biosciences stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $119.00, for a total value of $595,000.00. Following the transaction, the chief financial officer now directly owns 9,811 shares of the company's stock, valued at $1,167,509. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Keith W. Marshall sold 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $119.00, for a total transaction of $595,000.00. Following the completion of the sale, the chief financial officer now directly owns 9,811 shares in the company, valued at $1,167,509. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Mark C. Mckenna sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $118.99, for a total transaction of $2,974,750.00. Following the sale, the chief executive officer now owns 55,144 shares of the company's stock, valued at $6,561,584.56. The disclosure for this sale can be found here. 13.08% of the stock is currently owned by insiders.

Prometheus Biosciences Profile

(Get Rating)

Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.

See Also

• Get a free copy of the StockNews.com research report on Prometheus Biosciences (RXDX)
• Is Seagate Technology Signaling the End of its Normalization?
• eHealth Stock Rises from the Ashes. Time to Get In?
• Can Yext A.I. Search Platform Drive Growth in 2023?
• Cassava Sciences Stock Undervalued with Its $124 Price Target?
• Constellation Brands: Are Consumers Trading Down for Rail Drinks?

Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.